These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 8812735)

  • 21. Specific antibody titer alters the effectiveness of intrathecal enzyme replacement therapy in canine mucopolysaccharidosis I.
    Dickson PI; Ellinwood NM; Brown JR; Witt RG; Le SQ; Passage MB; Vera MU; Crawford BE
    Mol Genet Metab; 2012 May; 106(1):68-72. PubMed ID: 22402327
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Changes in hair morphology of mucopolysaccharidosis I patients treated with recombinant human alpha-L-iduronidase (laronidase, Aldurazyme).
    Kloska A; Bohdanowicz J; Konopa G; Tylki-Szymńska A; Jakóbkiewicz-Banecka J; Czartoryska B; Liberek A; Wegrzyn A; Wegrzyn G
    Am J Med Genet A; 2005 Dec; 139(3):199-203. PubMed ID: 16283671
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enzyme replacement in a canine model of Hurler syndrome.
    Shull RM; Kakkis ED; McEntee MF; Kania SA; Jonas AJ; Neufeld EF
    Proc Natl Acad Sci U S A; 1994 Dec; 91(26):12937-41. PubMed ID: 7809150
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Continuous infusion of enzyme replacement therapy is inferior to weekly infusions in MPS I dogs.
    Passage MB; Krieger AW; Peinovich MC; Lester T; Le SQ; Dickson PI; Kakkis ED
    J Inherit Metab Dis; 2009 Dec; 32 Suppl 1(Suppl 1):S253-8. PubMed ID: 19562502
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enzyme replacement therapy started at birth improves outcome in difficult-to-treat organs in mucopolysaccharidosis I mice.
    Baldo G; Mayer FQ; Martinelli BZ; de Carvalho TG; Meyer FS; de Oliveira PG; Meurer L; Tavares A; Matte U; Giugliani R
    Mol Genet Metab; 2013 May; 109(1):33-40. PubMed ID: 23562162
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ocular lesions in canine mucopolysaccharidosis I and response to enzyme replacement therapy.
    Newkirk KM; Atkins RM; Dickson PI; Rohrbach BW; McEntee MF
    Invest Ophthalmol Vis Sci; 2011 Jul; 52(8):5130-5. PubMed ID: 21436264
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immune response to enzyme replacement therapy: single epitope control of antigen distribution from circulation.
    Glaros EN; Turner CT; Parkinson EJ; Hopwood JJ; Brooks DA
    Mol Genet Metab; 2002; 77(1-2):127-35. PubMed ID: 12359140
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gene therapy for a mucopolysaccharidosis type I murine model with lentiviral-IDUA vector.
    Di Domenico C; Villani GR; Di Napoli D; Reyero EG; Lombardo A; Naldini L; Di Natale P
    Hum Gene Ther; 2005 Jan; 16(1):81-90. PubMed ID: 15703491
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diffusion tensor imaging and myelin composition analysis reveal abnormal myelination in corpus callosum of canine mucopolysaccharidosis I.
    Provenzale JM; Nestrasil I; Chen S; Kan SH; Le SQ; Jens JK; Snella EM; Vondrak KN; Yee JK; Vite CH; Elashoff D; Duan L; Wang RY; Ellinwood NM; Guzman MA; Shapiro EG; Dickson PI
    Exp Neurol; 2015 Nov; 273():1-10. PubMed ID: 26222335
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification and molecular characterization of alpha-L-iduronidase mutations present in mucopolysaccharidosis type I patients undergoing enzyme replacement therapy.
    Yogalingam G; Guo XH; Muller VJ; Brooks DA; Clements PR; Kakkis ED; Hopwood JJ
    Hum Mutat; 2004 Sep; 24(3):199-207. PubMed ID: 15300847
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immune response hinders therapy for lysosomal storage diseases.
    Ponder KP
    J Clin Invest; 2008 Aug; 118(8):2686-9. PubMed ID: 18654672
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enzyme replacement therapy in mucopolysaccharidosis type I.
    Miebach E
    Acta Paediatr Suppl; 2005 Mar; 94(447):58-60; discussion 57. PubMed ID: 15895714
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bone marrow transplantation in canine mucopolysaccharidosis I. Effects within the central nervous system.
    Shull RM; Hastings NE; Selcer RR; Jones JB; Smith JR; Cullen WC; Constantopoulos G
    J Clin Invest; 1987 Feb; 79(2):435-43. PubMed ID: 3100576
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Myoblast gene therapy in canine mucopolysaccharidosis. I: Abrogation by an immune response to alpha-L-iduronidase.
    Shull RM; Lu X; McEntee MF; Bright RM; Pepper KA; Kohn DB
    Hum Gene Ther; 1996 Aug; 7(13):1595-603. PubMed ID: 8864760
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Morphologic and biochemical studies of canine mucopolysaccharidosis I.
    Shull RM; Helman RG; Spellacy E; Constantopoulos G; Munger RJ; Neufeld EF
    Am J Pathol; 1984 Mar; 114(3):487-95. PubMed ID: 6320652
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The designer aminoglycoside NB84 significantly reduces glycosaminoglycan accumulation associated with MPS I-H in the Idua-W392X mouse.
    Wang D; Belakhov V; Kandasamy J; Baasov T; Li SC; Li YT; Bedwell DM; Keeling KM
    Mol Genet Metab; 2012 Jan; 105(1):116-25. PubMed ID: 22056610
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biomarker responses correlate with antibody status in mucopolysaccharidosis type I patients on long-term enzyme replacement therapy.
    Langereis EJ; van Vlies N; Church HJ; Geskus RB; Hollak CE; Jones SA; Kulik W; van Lenthe H; Mercer J; Schreider L; Tylee KL; Wagemans T; Wijburg FA; Bigger BW
    Mol Genet Metab; 2015 Feb; 114(2):129-37. PubMed ID: 25467058
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neonatal tolerance induction enables accurate evaluation of gene therapy for MPS I in a canine model.
    Hinderer C; Bell P; Louboutin JP; Katz N; Zhu Y; Lin G; Choa R; Bagel J; O'Donnell P; Fitzgerald CA; Langan T; Wang P; Casal ML; Haskins ME; Wilson JM
    Mol Genet Metab; 2016 Sep; 119(1-2):124-30. PubMed ID: 27386755
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intranasal Adeno-Associated Virus Mediated Gene Delivery and Expression of Human Iduronidase in the Central Nervous System: A Noninvasive and Effective Approach for Prevention of Neurologic Disease in Mucopolysaccharidosis Type I.
    Belur LR; Temme A; Podetz-Pedersen KM; Riedl M; Vulchanova L; Robinson N; Hanson LR; Kozarsky KF; Orchard PJ; Frey WH; Low WC; McIvor RS
    Hum Gene Ther; 2017 Jul; 28(7):576-587. PubMed ID: 28462595
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase).
    Wraith JE; Clarke LA; Beck M; Kolodny EH; Pastores GM; Muenzer J; Rapoport DM; Berger KI; Swiedler SJ; Kakkis ED; Braakman T; Chadbourne E; Walton-Bowen K; Cox GF
    J Pediatr; 2004 May; 144(5):581-8. PubMed ID: 15126990
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.